Calliditas Therapeutics AB (publ)
Calliditas Therapeutics AB (publ) (CALT) Revenue
Annual & quarterly revenue history · segment & region breakdown
CALT · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsCalliditas Therapeutics AB (publ) trailing twelve-month (TTM) revenue is $1.60B, an increase of 50.32% year-over-year from $1.21B in FY2023.
Revenue trend
2023 – 2015 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2023-12-31 | $1.21B | +$0.40B | +50.32% |
| 2022-12-31 | $0.80B | +$0.57B | +250.07% |
| 2021-12-31 | $0.23B | +$0.23B | +26141.08% |
| 2020-12-31 | $0.00B | -$0.18B | -99.53% |
| 2019-12-31 | $0.18B | +$0.18B | — |
| 2018-12-31 | $0.00B | +$0.00B | — |
| 2017-12-31 | $0.00B | -$0.00B | -100.00% |
| 2016-12-31 | $0.00B | +$0.00B | +3.97% |
| 2015-12-31 | $0.00B | — | — |
Compare revenue vs peers
BiotechnologyCompare CALT revenue against listed peers. Click any row to open that company's revenue tab.
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Calliditas Therapeutics AB (publ) receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Calliditas Therapeutics AB (publ) reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in SEK.
Data sourced from Calliditas Therapeutics AB (publ)'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
CALT revenue · 4 questionsCALT's trailing twelve-month (TTM) revenue is $1.60B. That is an increase of 50.32% year-over-year from $1.21B in FY2023.
▸ Source: FMP · Calliditas Therapeutics AB (publ) SEC filings · GAAP · Calliditas Therapeutics AB (publ) SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026